Medicina molecular trisomia 21

DOI: 10.1002/pd.2922

ORIGINAL ARTICLE

Selective analysis of cell-free DNA in maternal blood for evaluation of fetal trisomy
Andrew B. Sparks1†, Eric T. Wang1†, Craig A. Struble1, Wade Barrett1, Renee Stokowski1, Celeste McBride1, Jacob Zahn1, Kevin Lee1, Naiping Shen1, Jigna Doshi1, Michel Sun1, Jill Garrison1, Jay Sandler1, Desiree Hollemon1, Patrick Pattee1, Aoy Tomita-Mitchell2, Michael Mitchell2, John Stuelpnagel1, Ken Song1* and Arnold Oliphant1
1 2

Aria Diagnostics, Inc., 5945 Optical Court, San Jose, CA 95138, USA. Medical College of Wisconsin, Milwaukee, WI 53226, USA. *Correspondence to: Ken Song. E-mail: [e-mail] † Authors contributed equally to the work.

ABSTRACT
Objective To develop a novel prenatal assay based on selective analysis of cell-free DNA in maternal blood for evaluation of fetal Trisomy 21 (T21) and Trisomy 18 (T18). Methods Two hundred ninety-eight pregnancies, including 39 T21 and seven T18 confirmed fetal aneuploidies, were analyzed using a novel, highly multiplexed assay, termed digital analysis of selected regions (DANSR™). Cell-free DNA from maternal blood samples was analyzed using DANSR assays for loci on chromosomes 21 and 18. Products from 96 separate patients were pooled and sequenced together. A standard Z-test of chromosomal proportions was used to distinguish aneuploid samples from average-risk pregnancy samples. DANSR aneuploidy discrimination was evaluated at various sequence depths. Results At the lowest sequencing depth, corresponding to 204 000 sequencing counts per sample, average-risk cases where distinguished from T21 and T18 cases, with Z statistics for all cases exceeding 3.6. Increasing the sequencing depth to 410 000 counts per sample substantially improved separation of aneuploid and average-risk cases. A further increase to 620 000 counts per sample resulted in only marginal improvement. This depth of sequencing represents less than 5% of that required by massively parallel shotgun